Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for Secondary Prophylaxis of CMV in Solid Organ Transplant Recipients
NCT05626530Phase 4Completed
- Sponsor
- Tufts Medical Center
- Start
- Feb 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of letermovir in cytomegalovirus infection (CMV), sponsored by Tufts Medical Center. Started Feb 2023; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05626530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626530.